On the recordMarch 5, 2012
These capital-intensive firms face unique challenges in raising the significant amounts of money necessary to complete clinical trials and complete development of cutting-edge drugs.
Source
congress.govThese capital-intensive firms face unique challenges in raising the significant amounts of money necessary to complete clinical trials and complete development of cutting-edge drugs.
Corker highlights challenges faced by biotech firms in raising capital.
Share
More from Bob Corker
I rise to speak on the issue before us. On every occasion, I too have done what is necessary to keep us from alienating our ally Saudi Arabia. I think I was the last man standing, during the Obama administration, in my trying to make sure…
I thank the Senator. The PRESIDING OFFICER. The majority leader. ____________________
I ask unanimous consent that the joint resolution be considered read a third time. The PRESIDING OFFICER. Without objection, it is so ordered. The joint resolution was ordered to be engrossed for a third reading and was read the third time.